Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients

Inclusion Criteria: 1. Age over 19 years 2. Patients with adequate HD (Kt/V \> 1.2) 3. Maintenance patients undergoing HD with chronic pruritus 4. Mean visual analog scale (VAS) over 4 of the last 5 days in the 14-day pre-observation period 5. Participants who allowed to continue the anti-pruritic drug treatment at the same dosage and administration schedule as used at baseline throughout the study period 6. Patients who agreed to participate in this trial and had written an informed consent Exclusion Criteria: 1. Intact parathyroid hormone (iPTH) \> 1000 pg/mL within 1 month 2. Serum potassium \> 7.0 mg/dL 3. HIV Ab (+) 4. Aspartate transaminase (AST) (glutamic oxaloacetic transaminase) or alanine transaminase (ALT) (glutamic pyruvic transaminase) \> 3 times the upper limit of normal 5. Scheduled to have kidney transplantation within 3 months 6. Cancer history with current treatment 7. Active infection with current treatment 8. Current itching with dermatologic diseases other than uremic pruritus 9. Pregnancy, childbearing potential during the study period, or breastfeeding 10. Allergy or hypersensitivity reaction to PG102P 11. History of participating another clinical trial within 2 months or planning to participate another clinical trial 12. Not eligible to participate this trial as researchers' decision